Skip to main content

Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.

Publication ,  Journal Article
Armstrong, AJ; George, DJ
Published in: Prostate Cancer Prostatic Dis
June 2010

In 2009, castration-resistant metastatic prostate cancer continues to account for more deaths in US men than any other cancer apart from lung cancer. Although novel targeted molecular, hormonal and immunologic agents are accelerating in their development in this disease, docetaxel and prednisone remain the standard palliative regimen for the majority of men who have progressed despite hormonal therapies. Thus, understanding the practical and often subtle issues of docetaxel initiation, duration of therapy, cessation of therapy and treatment holidays is critical for the informed use of this US Food and Drug Administration-approved regimen. In this review we address these topics in light of prognostic and predictive factors to help guide the rational use of docetaxel chemotherapy in men with this aggressive disease.

Duke Scholars

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2010

Volume

13

Issue

2

Start / End Page

108 / 116

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Taxoids
  • Substance Withdrawal Syndrome
  • Prostatic Neoplasms
  • Prognosis
  • Prednisone
  • Orchiectomy
  • Neoplasm Metastasis
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., & George, D. J. (2010). Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis, 13(2), 108–116. https://doi.org/10.1038/pcan.2009.62
Armstrong, A. J., and D. J. George. “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.Prostate Cancer Prostatic Dis 13, no. 2 (June 2010): 108–16. https://doi.org/10.1038/pcan.2009.62.
Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):108–16.
Armstrong, A. J., and D. J. George. “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.Prostate Cancer Prostatic Dis, vol. 13, no. 2, June 2010, pp. 108–16. Pubmed, doi:10.1038/pcan.2009.62.
Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):108–116.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2010

Volume

13

Issue

2

Start / End Page

108 / 116

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Taxoids
  • Substance Withdrawal Syndrome
  • Prostatic Neoplasms
  • Prognosis
  • Prednisone
  • Orchiectomy
  • Neoplasm Metastasis
  • Male